NEW YORK (
CHANGE IN RATINGS
downgraded at Jefferies to Hold from Buy, Jefferies said. $34 price target. Weaker data and limited uplift from suites. Hold rating.
upgraded at Mizuho to Buy, Mizuho said. $22 price target. Business will likely bottom out in the fourth quarter.
upgraded at BMO from Market Perform to Outperform, BMO Capital said. $120 price target. Global growth appears to be stabilizing.
downgraded at Piper from Neutral to Underweight, Piper Jaffray said. Valuation call, based on a $49 price target.
downgraded at UBS to Neutral from Buy, UBS said. $60 price target. Long term outlook dims.
Devon Energy downgraded at Citigroup. DVN was downgraded to Neutral from Buy, Citigroup said. $62 price target. Lower costs, but reining in production growth outlook.
upgraded at UBS to Neutral from Sell, UBS said. $30 price target. Shares now reflect a lower dvidend.
upgraded at Baird from Underperform to Neutral, Robert Baird said. Valuation call, based on a $13 price target.
upgraded at BMO from Underperform to Market Perform, BMO Capital said. $23 price target. Near-term visibility is improving.
upgraded at Cantor from Hold to Buy, Cantor Fitzgerald said. $21 price target. Company is cutting costs and is leveraged to higher carrier spending.
upgraded at UBS to Buy from Neutral, UBS said. $38 price target. Improved relative growth rate supports raised valuation.
downgraded at Wedbush from Outperform to Neutral, Wedbush said. $20 price target. Estimates also cut, as the company has reduced visibility.
upgraded at BMO to Outperform, BMO Capital said. Valuation call, based on a $94 price target.
downgraded at Caris from Buy to Above Average, Caris & Co. said. $129 price target. Company is seeing slower demand for consumer healthcare and nutritionals.
PSS World Medical
( PSSI) downgraded at UBS to Neutral from Buy, UBS said. $29 price target. 10Q reveals inline results.
upgraded at Argus from Hold to Buy, Argus said. $62 price target. Company has made several smart strategic decisions.
upgraded at Citigroup to Buy from Neutral, Citigroup said. $60 price target. Solid Q3 beat and 2013 guidance.
downgraded at Cantor from Hold to Sell, Cantor FItzgerald said. $20 price target. Adcetris is growing slower than expected.
STOCK COMMENTS / EPS CHANGES
numbers lowered at OppenheimerShares of AH now seen reaching $15, Oppenheimer said. Estimates also lowered on 3Q results. Outperform rating.
numbers lowered at Jefferies. Shares of AUXL now seen reaching $29, Jefferies said. Estimates also lowered on Testim miss. Buy rating.
estimates, target reduced at Morgan Stanley. Shares of CVC now seen reaching $15, according to Morgan Stanley. Estimates also cut, as the company is realizing lower margins. Underweight rating.
numbers increased at Credit Suisse. HFC estimates were raised through 2015, Credit Suisse said. Company is seeing higher refining growth. Neutral rating and new $53 price target.
numbers raised at Citigroup. Shares of MPEL now seen reaching $22.50, Citigroup said. Estimates also increased on Q3 beat. Buy rating.
numbers cut at Citigroup. Shares of NYX now seen reaching $25, Citigroup said. Estimates also lowered as environment remains challenging. Neutral rating.
estimates, target reduced at Credit Suisse. Shares of RP now seen reaching $27, according to Credit Suisse. Estimates also cut, gvien product delays. Outperform rating.
target raised at Jefferies. Shares of WLP now seen reaching $64, Jefferies said. Results show signs of stability. Hold rating.
WellPoint numbers lowered at Oppenheimer. Shares of WLP now seen reaching $73, Oppenheimer said. Estimates also lowered on 3Q results. Outperform rating.
Wellpoint estimates, target boosted at BMO. Shares of WLP now seen reaching $65, according to BMO Capital. Estimates also upped, as the company is keeping a tight lid on costs.
>To submit a news tip, email:
READERS ALSO LIKE:
and become a fan on
This article was written by a staff member of TheStreet.